Imusyn is a biotech company focused on alloproteomics to advance allogeneic cellular therapies. The company is primarily focused on the development and production of recombinant proteins from polymorphic genetic systems, including MHC genes, blood group genes, and many other immune response genes. The Company’s proprietary recombinant protein manufacturing technology meets the needs of customers in the medical and life science markets for advanced diagnostics and immunotherapies.
